SESSION TITLE: Late-Breaking Abstracts
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 25, 2016 at 08:45 AM - 10:00 AM
PURPOSE: Acute exacerbations, marked by a rapid decline in lung function and poor patient-reported outcomes, are a cause of considerable morbidity and mortality associated with COPD, and incur significant healthcare utilization and associated costs. Here, we report the reduction in moderate or severe exacerbations with indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in COPD patients with ≥1 and 0-1 exacerbations in the previous year, from the FLAME and LANTERN studies, respectively.